Findings

What do systematic reviews say?

44 questions · 58 findings · 3 reviews

No studies found 13 · 22.4%GRADE not reported 3 · 5.2%Very low 7 · 12.1%Low 11 · 19%Moderate 17 · 29.3%High 7 · 12.1%

Symptomatic DVT · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).

1 finding from 1 review

Total VTE · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower any VTE compared with placebo (high certainty).

1 finding from 1 review

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with placebo (moderate certainty).

1 finding from 1 review

Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin showed no clear difference in clinically relevant bleeding compared with placebo (moderate certainty).

1 finding from 1 review